Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology

[Image: see text] GlycoConnect technology can be readily adapted to provide different drug-to-antibody ratios (DARs) and is currently also evaluated in various clinical programs, including ADCT-601 (DAR2), MRG004a (DAR4), and XMT-1660 (DAR6). While antibody-drug conjugates (ADCs) typically feature a...

Descripción completa

Detalles Bibliográficos
Autores principales: de Bever, Laureen, Popal, Sorraya, van Schaik, Jord, Rubahamya, Baron, van Delft, Floris L., Thurber, Greg M., van Berkel, Sander S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020967/
https://www.ncbi.nlm.nih.gov/pubmed/36857521
http://dx.doi.org/10.1021/acs.bioconjchem.2c00611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020967/
https://www.ncbi.nlm.nih.gov/pubmed/36857521
http://dx.doi.org/10.1021/acs.bioconjchem.2c00611

Ejemplares similares